Recent News

• 09.10.2025 - Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation
• 08.20.2025 - Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences
• 08.19.2025 - Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team
• 08.13.2025 - Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania
• 08.11.2025 - Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events
• 04.03.2025 - Greenwich LifeSciences Provides Global Update on FLAMINGO-01
• 04.02.2025 - Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial
• 03.27.2025 - Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026
• 03.17.2025 - Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01
• 02.10.2025 - Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01

Recent Filings

• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.24.2025 - 8-K Current report
• 05.20.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.15.2025 - NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
• 04.29.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.15.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 04.08.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.31.2025 - NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405